Press Releases

BioIVT to Host a Webinar on Optimizing Liquid Biopsy Research

Webinar will discuss the importance of using standardized collection protocols and a diverse donor base to validate biomarkers and ensure their clinical utility.

Creative Proteomics Launches State-of-the-Art Peptide Sequencing Service to Advance Proteomics Research

New hot start isothermal mixes boost sensitivity, specificity, and speed of DNA target detection

PCR Biosystems, a leading PCR reagent developer, has launched a new range of Bst polymerase reagents that offer greater sensitivity, speed, and specificity in all isothermal amplification applications.

Creative Proteomics Introduces Mature Solutions for Membrane Protein Identification

Creative Proteomics Leads the Way with Cutting-Edge RNA Pull Down Service

Coya Therapeutics Licenses Exclusive Worldwide rights to Exosome Engineering Technology (EET) from Carnegie Mellon University (CMU)

Novel proprietary EET platform extends Coya Therapeutics' pipeline beyond Neurodegenerative disorders to include autoimmune disorders and cancer while expanding Coya’s optionality for potential non-dilutive business development and strategic partnerships with companies seeking novel ways to deliver cargo/drugs in a targeted fashion.

Cytel continues expansion of market access and medical communication capabilities with the acquisition of co.faktor

Cytel Inc. has acquired the Berlin-based company co.faktor GmbH.

Creative Biostructure Announces New Method for Producing CRAL-TRIO Domain-Containing Proteins Using Virus-Like Particles

Matexcel Launches New Line of Natural Extract Peptide Products for Research Use

Profacgen Announces New Technology for Membrane Protein Production

Creative Enzymes Unveils Custom Blends Product Line for Bioprocessing Solutions

Creative Enzymes Launches Diamine Oxidase (Food-Grade) for Enhanced Food Safety and Digestive Health

CD Genomics Redefines RNA Sequencing with Revolutionary Ultra Low RNA Sequencing Technology

CD Genomics Unveils Genotyping by Sequencing (GBS) -Revolutionizing Genomic Research

CD BioGlyco Launches Anti-glycan Antibody Development Services to Advance Biomedical Research

CD Genomics Unveils Cutting-Edge DNA 6mA Sequencing Service for Epigenomic Research

Expanding Research Frontiers: CD Formulation Enables In Vitro Cytotoxicity Testing for Microspheres and Microneedles

Alfa Chemistry: Transforming Research Possibilities through Instrumental Analytical Reagents

MERCY BIOANALYTICS ADDS MARKETING AND PORTFOLIO MANAGEMENT LEADERSHIP TO SUPPORT DIAGNOSTIC TEST DEVELOPMENT AND COMMERCIALIZATION

Mercy BioAnalytics, Inc. - a pioneer in extracellular vesicle-based liquid biopsies for early cancer detection - added two executives in marketing and portfolio management as it continues rapid development of its novel test portfolio and looks ahead to commercialization.

NICE RECOMMENDS LILLY’S MIRIKIZUMAB (OMVOH ®▼) FOR THE TREATMENT OF ELIGIBLE ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Mirikizumab is the first IL-23p19 targeted biologic recommended by NICE for use within NHS England and Wales for treating moderately to severely active ulcerative colitis in adults.1,2. In two randomised, double-blind, placebo-controlled phase 3 trials, LUCENT-1 and LUCENT-2, mirikizumab achieved primary and key secondary endpoints, including sustained clinical remission. Decreases in bowel urgency severity were observed as early as week 2 in patients treated with mirikizumab versus placebo in LUCENT-1.2 Mirikizumab has been recommended through the NICE cost-comparison process meaning NHS England and commissioning groups have agreed to provide funding to implement this guidance within 30 days from publication of the technology appraisal guidance (TAG) rather than the standard 90 days, providing faster access to a new treatment option for eligible adults living with moderately to severely active ulcerative colitis1